Learn
Are peptides legal in 2026? How U.S. rules work
Published · Editorial team
Medical review pending · Last updated
"Are peptides legal?" has no single answer, because "peptides" covers everything from insulin to products sold online as research chemicals. Under U.S. federal law, what matters is whether a peptide is an FDA-approved drug, whether a licensed pharmacy may lawfully compound it, or neither. This guide explains each path as of the date above. It is general information, not legal advice.
The four situations at a glance
| Situation | Examples | Can a clinician prescribe it? |
|---|---|---|
| FDA-approved peptide drug | Semaglutide (Wegovy®), tirzepatide (Zepbound®), tesamorelin (Egrifta®), bremelanotide (Vyleesi®) | Yes, if appropriate. Use outside the label is a clinical decision. |
| Compoundable under section 503A | Sermorelin (the active ingredient of a formerly FDA-approved drug) | Yes, compounded by a state-licensed pharmacy for an individual patient. Not FDA-approved. |
| Covered by the HHS interim policy | BPC-157, TB-500, MOTS-c, KPV, Epitalon, Semax | Yes, only if the policy's conditions are met. Not FDA-approved. |
| None of the above | CJC-1295, ipamorelin, blends, and "research use only" products | No lawful compounding pathway today. |
1. FDA-approved peptide drugs
Many prescription medicines are peptides. When a peptide drug is FDA-approved, FDA has reviewed evidence of its safety and effectiveness for specific uses listed on its label. A licensed clinician can prescribe it, and a pharmacy dispenses the approved product.
2. Compounding under section 503A
Compounding means a pharmacist or physician combines or alters ingredients to make a medicine for an individual patient. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacy may compound with a bulk drug substance (the raw active ingredient) only if it:
- Meets an applicable U.S. Pharmacopeia or National Formulary monograph, or
- Is a component of an FDA-approved drug, or
- Appears on FDA's 503A bulk drug substances list.
Outsourcing facilities registered under section 503B follow different rules, tied to FDA's drug shortage list and a separate 503B bulks list. In both cases the compounded product is not FDA-approved. Sermorelin is an example of the second route: it was the active ingredient in Geref®, which FDA approved and later determined was not withdrawn for safety or effectiveness reasons.
3. FDA's nomination categories
While FDA builds the 503A bulks list, it sorts nominated substances into three categories, updated over time:
| Category | Meaning | Examples (as of FDA's May 2026 update) |
|---|---|---|
| Category 1 | Under evaluation | Includes GHK-Cu for non-injectable routes |
| Category 2 | Raises significant safety risks | Ibutamoren (MK-677), kisspeptin-10 |
| Category 3 | Nominated without adequate support | Includes GHRP-2 and GHRP-6 |
In April 2026, a group of peptides was removed from Category 2 after their nominations were withdrawn. HHS noted that neither the earlier placement nor the removal changed their status under section 503A on its own. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides for the 503A bulks list and voted against DSIP (emideltide).
4. The HHS interim peptide policy
HHS announced the policy on October 28, 2026, and the notice was published in the Federal Register on October 30, 2026 (91 FR 68526). It covers six peptides: BPC-157, TB-500, MOTS-c, KPV, Epitalon, and Semax. HHS said it does not intend to take enforcement action against state-licensed pharmacies and physicians that compound them when all of the policy's conditions are met. The conditions include:
- An active ingredient from an FDA-registered facility, with a valid certificate of analysis
- A single active ingredient per product (no blends)
- A prescription for an individual patient
- Only the routes HHS listed for each peptide (below)
- Required labeling, including "This is a compounded drug product. Not for resale."
- Reporting of adverse events to FDA's MedWatch program
| Peptide | Routes covered by the policy |
|---|---|
| BPC-157 | Subcutaneous, intramuscular, oral, topical |
| TB-500 | Subcutaneous, intramuscular |
| MOTS-c | Subcutaneous, intramuscular |
| KPV | Topical, oral |
| Epitalon | Subcutaneous, intramuscular, in intermittent courses |
| Semax | Intranasal |
The policy is not binding, it is not an FDA approval, and it does not mean these peptides have been shown to be safe or effective. Human evidence for most of them is limited. HHS said it may revisit the policy if safety signals arise.
What is still not allowed
- Peptides sold as "research use only" or "not for human consumption"
- Multi-ingredient peptide blends under the HHS policy
- Peptides with no lawful compounding pathway, such as CJC-1295 and ipamorelin (see our exclusions list)
- Copies of commercially available FDA-approved drugs, which federal law restricts
What this means for you
If you are curious about a peptide, start with a licensed clinician rather than a website that sells vials. A clinician can tell you whether a peptide fits your health history, whether an FDA-approved option exists, and what is known about its risks. If a compounded peptide is prescribed, it should come from a state-licensed pharmacy with your name on the label. Report side effects to your clinician and to FDA MedWatch.
Rules change often. This page reflects federal sources as of the date above and is not legal advice. State laws may be stricter.
Frequently asked questions
Is BPC-157 legal in 2026?
BPC-157 is not FDA-approved. Under the HHS interim policy announced October 28, 2026 and published in the Federal Register on October 30, 2026, HHS does not intend to take enforcement action when a state-licensed pharmacy or physician compounds it for an individual patient's prescription and meets the policy's conditions. The policy is non-binding and can change.
Are "research use only" peptides legal to use?
Products labeled "for research use only" or "not for human consumption" are not approved or compounded for people, and FDA does not review them. They are not a lawful substitute for a prescription.
Are compounded peptides FDA-approved?
No. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before they are dispensed.
Is the HHS peptide policy permanent?
No. It is an interim enforcement-discretion policy while FDA considers adding the six peptides to the 503A bulks list through rulemaking. HHS said it may revise the policy, for example if safety concerns arise.
Is this legal advice?
No. This is general information about federal rules as of the date above. State laws and pharmacy board rules also apply. Ask a qualified attorney about your situation.
Sources
- Federal Register: HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526, published Oct 30, 2026)
- HHS: Enforcement discretion policy text and Appendices A-B (PDF)
- FDA: Bulk drug substances nominated for use in compounding under section 503A (Categories 1-3, PDF)
- FDA: Bulk drug substances used in compounding (503A and 503B rules)
- FDA: Compounding and the FDA, questions and answers
- Federal Register 2026-07361: PCAC notice of meeting on bulk drug substances nominated for the 503A list (Apr 16, 2026)
- FDA: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026
- Federal Register: FDA determination that Geref (sermorelin acetate) was not withdrawn for safety or effectiveness (Mar 4, 2013)
Sources are listed for reference and do not imply endorsement. Regulatory status can change; check the date above.
This article is for education only and is not medical or legal advice. A licensed clinician decides whether any treatment is appropriate for you.